About
About ReNeuron Group plc
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Visit company website
5 years, 4 months ago
ReNeuron Group plc is currently in a long term downtrend where the price is trading 1.7% below its 200 day moving average.
From a valuation standpoint, the stock is 14.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 509.9.
ReNeuron Group plc's total revenue sank by 0.0% to $3M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 55.7% to $-1M since the same quarter in the previous year.
Based on the above factors, ReNeuron Group plc gets an overall score of 1/5.